Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere. In Japan it is produced by Dain
{{Drugbox | verifiedrevid = 464380887 | image = Repaglinide.svg | image_class = skin-invert-image | image2 = Repaglinide ball-and-stick.png | image_class2 = bg-transparent
| tradename = Prandin, Novonorm, Enyglid, others | Drugs.com = | MedlinePlus = a600010 | licence_EU = yes | DailyMedID = Repaglinide | licence_US = Prandin | pregnancy_AU = C | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BX02 | legal_AU = S4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | legal_EU = Rx-only
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).